Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2020-08-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
반기보고서 (2020.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company PharmAbcine (파멥신) for the period ending June 30, 2020. It contains comprehensive financial data, business overviews, capital structure, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2020
2020-08-14 Korean
타법인주식및출자증권취득결정(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from a Korean company (Pharmabcine) regarding the acquisition of shares in another corporation (a subsidiary). This type of disclosure, specifically titled '타법인주식및출자증권취득결정' (Decision to acquire shares and equity securities of another corporation), is a standard corporate disclosure filed with the Korea Exchange (KRX). Since it does not fit into specific categories like M&A (which usually implies a merger or takeover of a business entity rather than a capital injection into a subsidiary) or other specialized categories, it falls under the general regulatory filing category.
2020-07-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. It details the share ownership and changes in holdings (specifically the acquisition of bonus shares) by an executive (Choi Jun-hee) of PharmAbcine. This type of filing is classified as a Director's Dealing (DIRS) report, as it documents insider share transactions.
2020-07-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/KRX). It details the share ownership and changes in holdings (specifically the acquisition of bonus shares) by a company executive (Park Hyunsun). This type of filing is a standard regulatory disclosure for insider holdings, which falls under the 'Director's Dealing' category in the provided schema.
2020-07-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the shareholding changes of an individual (Lee Dong-sup, an executive/director) in the company PharmAbcine. This is a standard regulatory filing for insider trading/shareholding disclosure, which falls under the 'Director's Dealing' category.
2020-07-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. This type of filing is a mandatory disclosure by company insiders (directors/executives) regarding their personal shareholdings and changes therein. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2020-07-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.